Search hospitals > Ontario > OTTAWA
Ottawa Hospital Research Institute
Claim this profileOTTAWA, Ontario K1H 8L6
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
Conducts research for Colorectal Cancer
219 reported clinical trials
26 medical researchers
Summary
Ottawa Hospital Research Institute is a medical facility located in OTTAWA, Ontario. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer and other specialties. Ottawa Hospital Research Institute is involved with conducting 219 clinical trials across 274 conditions. There are 26 research doctors associated with this hospital, such as John Hilton, MD, Dar Dowlatshahi, MD, Scott A Laurie, and Paul Wheatley-Price, MD.Area of expertise
1Cancer
Global LeaderTP53 positive
Stage IV
HER2 positive
2Lung Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
Top PIs
John Hilton, MDOttawa Hospital Research Institute7 years of reported clinical research
Studies Breast Cancer
Studies Non-Hodgkin's Lymphoma
12 reported clinical trials
33 drugs studied
Dar Dowlatshahi, MDOttawa Hospital Research Institute4 years of reported clinical research
Studies Stroke
Studies Ischemic Stroke
7 reported clinical trials
12 drugs studied
Scott A LaurieThe Ottawa Hospital3 years of reported clinical research
Studies Tumors
Studies Solid Tumors
6 reported clinical trials
12 drugs studied
Paul Wheatley-Price, MDThe Ottawa Hospital5 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
5 reported clinical trials
12 drugs studied
Clinical Trials running at Ottawa Hospital Research Institute
Non-Small Cell Lung Cancer
Bleeding
Prostate Cancer
Melanoma
Lymphoma
Skin Cancer
COVID-19
Coronavirus
Lung Cancer
Stroke
Amivantamab + Capmatinib
for Non-Small Cell Lung Cancer
The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD[s]) of the amivantamab and capmatinib combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection), and to evaluate the antitumor effect of the amivantamab and capmatinib combination therapy in mesenchymal-epithelial transition (MET) exon 14 skipping mutation and MET amplified NSCLC, when administered at the selected RP2CD(s) in Phase 2 (expansion).
Recruiting1 award Phase 1 & 25 criteria
Tobemstomig + Chemotherapy vs Pembrolizumab + Chemotherapy
for Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small-cell lung cancer (NSCLC) who are not eligible to receive curative surgery and/or definitive chemoradiotherapy.
Recruiting1 award Phase 210 criteria
JDQ443
for Non-Small Cell Lung Cancer
This study is being done to answer the following question: What are the effects of new treatments on non-small cell lung cancer before surgery?
Recruiting1 award Phase 217 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Ottawa Hospital Research Institute?
Ottawa Hospital Research Institute is a medical facility located in OTTAWA, Ontario. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer and other specialties. Ottawa Hospital Research Institute is involved with conducting 219 clinical trials across 274 conditions. There are 26 research doctors associated with this hospital, such as John Hilton, MD, Dar Dowlatshahi, MD, Scott A Laurie, and Paul Wheatley-Price, MD.